Digoxin
Brand names: Digoxin, Lanoxin
At a glance
- Medicare prescriptions, 2024
- 1,133,802
- Medicare drug cost
- $26.1M
- Average cost per prescription
- $23.06
- Clinicians who prescribed it
- 38,107
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
LANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. Increasing myocardial contractility in pediatric patients with heart failure. Control of resting ventricular rate in patients with chronic atrial fibrillation in adults.
From the FDA-approved prescribing information (label dated December 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Cardiology 29.3%
- Internal Medicine 18.2%
- Family Medicine 15.9%
- Nurse Practitioners 13.6%
- Interventional Cardiology 8.3%
- Cardiac Electrophysiology 4.0%
- Physician Assistants 3.8%
- Geriatric Medicine 2.1%
- Heart Failure & Transplant Cardiology 1.4%
- General Practice 1.1%
- Hospitalist 0.6%
- Nuclear Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 39% from 2019 to 2024.
Biggest change by state since 2019
- New Hampshire −23%
- North Dakota −24%
- Idaho −25%
- Delaware −30%
- Hawaii −31%
- Rhode Island (smallest change) −53%
- Puerto Rico (smallest change) −51%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Advanz Pharma (US) Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.0625 mg | orange round tablet, 5 mm | LANOXIN U3A |
| 0.125 mg | yellow round tablet, 6 mm, scored to split in 2 | LANOXIN Y3B |
| 0.1875 mg | blue round tablet, 6 mm | LANOXIN F3F |
| 0.25 mg | white round tablet, 7 mm, scored to split in 2 | LANOXIN X3A |
Marlex Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.125 mg | yellow round tablet, 6 mm, scored to split in 2 | N201 |
| 0.25 mg | white round tablet, 7 mm, scored to split in 2 | N202 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Mar 2024 · Novitium Pharma LLC · Class III
Failed Impurities/Degradation Specifications - Mar 2024 · Novitium Pharma LLC · Class III
Cross Contamination with Other Products:(mycophenolate mofetil).
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.